Back to News
Market Impact: 0.45

These Analysts Cut Their Forecasts On Newell Brands Following Q2 Results

NWLJPM
Corporate EarningsAnalyst EstimatesCorporate Guidance & OutlookCompany FundamentalsTax & TariffsAnalyst InsightsMarket Technicals & Flows
These Analysts Cut Their Forecasts On Newell Brands Following Q2 Results

Newell Brands reported Q2 adjusted EPS of 24 cents, in line with consensus, but sales of $1.935 billion missed estimates and were down 4.8% year-over-year. Despite meeting Q2 guidance ranges, the company lowered its Q3 adjusted EPS outlook to 16-19 cents (below 26-cent consensus) and full-year 2025 adjusted EPS guidance to 66-70 cents, citing higher tariff-related inventory costs. Notably, NWL shares gained 5.4% following the announcement, although analysts like JP Morgan and Canaccord Genuity maintained ratings but reduced their price targets.

Analysis

Newell Brands reported mixed second-quarter results, with adjusted EPS of 24 cents meeting consensus but quarterly sales of $1.935 billion missing estimates and declining 4.8% year-over-year. Despite management's commentary on meeting internal guidance and demonstrating agility in a challenging environment, the company's forward-looking outlook signals significant headwinds. The third-quarter adjusted EPS guidance of 16 to 19 cents is substantially below the 26-cent analyst consensus, and the full-year 2025 adjusted EPS forecast was lowered to a range of 66 to 70 cents, explicitly citing higher tariff-related inventory costs. In a counterintuitive market reaction, NWL shares gained 5.4% following the report, suggesting the negative guidance may have been partially priced in or that investors were relieved the company met its own Q2 targets. However, analysts at JP Morgan and Canaccord Genuity, while maintaining their Overweight/Buy ratings, tempered their optimism by lowering their price targets, reflecting a revised, more cautious view on the stock's valuation.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo